Cancer Treatment Evolution Fueled by CDK4/6 Inhibitors
The CDK4/6 inhibitor therapeutic sector exemplifies remarkable success in modern oncology, demonstrating how targeted therapeutic approaches can revolutionize treatment methodologies and improve patient survival rates
